{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.9","upperLimit":"228.0","value":"44.29"},{"groupId":"OG001","lowerLimit":"19.9","upperLimit":"147.0","value":"103.43"},{"groupId":"OG002","lowerLimit":"6.6","upperLimit":"210.6","value":"60.43"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"107"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"41"}],"units":"Participants"}],"description":"Time from first dose of IP to death due to any cause\n\nData will be collected and analyzed per Cohort Totals.","dispersionType":"Full Range","groups":[{"description":"CC220","id":"OG000","title":"Cohort D: Total"},{"description":"CC220 + DEX","id":"OG001","title":"Cohort H2"},{"description":"CC220 + DEX","id":"OG002","title":"Cohort I"}],"paramType":"MEDIAN","populationDescription":"Safety Population for Cohort D, Cohort H2 and Cohort I - as per protocol, the individual arms in the cohort would be combined for OS presentation","reportingStatus":"POSTED","timeFrame":"On Average of (Cohort D: 81.14 Cohort H2: 91.54 Cohort I: 74.20)Weeks","title":"Overall Survival for Cohort D, Cohort H2 and Cohort I","type":"SECONDARY","unitOfMeasure":"Weeks"}